SMMT FDA decision: Nov 13, 2026 (announced Nov 15)
Page updated ·next FDA decision on the calendar·Data as of Nov 19, 2026 12:24 AM ET
The FDA's own letter · Complete Response Letter, BLA 761524 (PDF), dated November 13, 2026, released under FDA's CRL transparency program. The company announced the decision on November 15, 2026; the FDA acted on November 13, 2026.
Sections the letter addresses (its own headings, read from the PDF's text layer; labeling and administrative sections omitted): Clinical/Statistical.
This page was first committed to pdufa.bio's public repository on Nov 17, 2026, 1:24 AM ET (public commit ce46f16). Dates on this page are the FDA's and the sponsor's; this line is ours.
Summit announced on November 15, 2026 that the FDA issued a Complete Response Letter on the BLA for ivonescimab with platinum-containing chemotherapy in EGFR-mutated NSCLC after EGFR TKI therapy.
Run-up into the decision (T-120 → T+1)
Daily close, T-120 (5/26/26) through T+1. Run-up high $18.42 on 9/14/26, low $12.43 on 8/20/26 (T-120 to T-1). Announced 11/15/26 (FDA action 11/13/26). Historical price action, not a forecast.
Key facts
FDA decision date2026-11-13
Announced2026-11-15
OutcomeCRL
Drug / candidateIvonescimab
IndicationWith platinum chemotherapy, EGFR-mutated locally advanced or metastatic non-squamous NSCLC after an EGFR TKI (HARMONi)
CompanySummit Therapeutics Inc.
Market-cap tierLarge
120-day run-up (T-120→T-1)-16.8%
Decision-day move-16.5%
Move measured onclose on the first trading day after 2026-11-15 (the announcement day), against the 2026-11-13 close
Cohort decision-day move (history)1.0% median (n=828)
The PDUFA goal date was November 14, 2026 (Summit 8-K, January 29, 2026). The FDA's Complete Response Letter is dated November 13, 2026, one day before the goal date; Summit announced it on November 15. Per Summit, the FDA found that substantial evidence of effectiveness is not established without a statistically significant overall survival improvement; HARMONi met its progression-free survival endpoint. A Complete Response Letter means the FDA will not approve the application in its present form; the sponsor can resubmit.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
FDA record of the action: the FDA issued a Complete Response Letter on November 13, 2026, per CRL letter CRL_BLA761524_20261113 (FDA letter). The sponsor announced it on November 15, 2026. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.
Specialist biotech funds holding SMMT, 13F for the quarter ended September 30, 2026
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
Questions
Was Ivonescimab approved by the FDA?
Not in this review cycle. On November 13, 2026 the FDA issued a Complete Response Letter, declining to approve the application for Ivonescimab in its current form. The company announced it on November 15, 2026. A CRL is not final; the primary source is linked on this page.
Which company is behind Ivonescimab?
Ivonescimab is a Summit Therapeutics Inc. (SMMT) program. The FDA decision came on November 13, 2026; the FDA's own record of the decision is linked on this page.
How did SMMT stock react to the FDA decision?
SMMT moved -16.5%, measured as the close on the first trading day after 2026-11-15 (the announcement day) against the 2026-11-13 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.